Daniel Busby
Stock Analyst at RBC Capital
(0.75)
# 3,358
Out of 4,479 analysts
6
Total ratings
50%
Success rate
-8.02%
Average return
Main Sectors:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals | Downgrades: Sector Perform | $16 → $4 | $7.47 | -46.45% | 2 | May 25, 2022 | |
| AGRX Agile Therapeutics | Maintains: Outperform | n/a | $1.41 | - | 1 | Jul 27, 2021 | |
| PFE Pfizer | Maintains: Sector Perform | n/a | $27.83 | - | 1 | Jun 17, 2021 | |
| MNKD MannKind | Initiates: Sector Perform | n/a | $5.03 | - | 1 | May 14, 2021 | |
| ABBV AbbVie | Reiterates: Outperform | $135 | $165.96 | -18.66% | 1 | May 3, 2021 |
Verrica Pharmaceuticals
May 25, 2022
Downgrades: Sector Perform
Price Target: $16 → $4
Current: $7.47
Upside: -46.45%
Agile Therapeutics
Jul 27, 2021
Maintains: Outperform
Price Target: n/a
Current: $1.41
Upside: -
Pfizer
Jun 17, 2021
Maintains: Sector Perform
Price Target: n/a
Current: $27.83
Upside: -
MannKind
May 14, 2021
Initiates: Sector Perform
Price Target: n/a
Current: $5.03
Upside: -
AbbVie
May 3, 2021
Reiterates: Outperform
Price Target: $135
Current: $165.96
Upside: -18.66%